SUBLIVAC Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study.

Trial Profile

SUBLIVAC Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2012

At a glance

  • Drugs Allergy immunotherapy; Birch pollen allergy immunotherapy
  • Indications Asthma; Hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2012 Actual patient numbers amended from 74 to 80 as reported by European Clinical Trials Database record.
    • 06 Feb 2012 Actual patient number (74) added as reported by ClinicalTrials.gov.
    • 15 Sep 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top